Inside Precision Medicine November 2, 2022
Arcturus Therapeutics, which has proprietary mRNA technology, has announced a strategic collaboration with CSL Seqirus, a global leader in the development, manufacture, and commercialization of vaccines for several infectious diseases. CSL Seqirus’ vaccine portfolio includes the world’s second largest influenza vaccine franchise. Seqirus is part of CSL Limited.
Arcturus will receive $200 million upfront and is eligible to receive over $1.3 billion in development milestones and over $3 billion in commercial milestones. In addition, the Company is eligible to receive a 40% net profit share for COVID-19 vaccine products and up to double-digit royalties for vaccines against flu, pandemic preparedness, and three other respiratory pathogens.
The collaboration combines CSL Seqirus’ global vaccine commercial and manufacturing infrastructure with Arcturus’ manufacturing experience...
Today's Sponsors
Today's Sponsor